Wang M, et al. - Since ibrutinib with rituximab (IR) combination induces durable responses in relapsed mantle cell lymphoma (MCL), researchers conducted this single institution phase II trial of IR with a short course (4 cycles) of R-HCVAD/R-MTX consolidation as frontline therapy in MCL to evaluate response rates after part-A (patients received IR induction). Participants in the study were previously untreated 50 young (≤65 years) MCL patients. In young MCL patients, IR followed by short course R-HCVAD/R-MTX as frontline treatment induced durable and profound remissions. This strategy showed excellent effectiveness and safety and minimized chemotherapy exposure.